The landscape of psilocybin policy reform is shifting faster than at any point in the past 50 years. Oregon became the first U.S. state to legalize psilocybin for therapeutic use in 2020, Colorado followed with decriminalization in 2022, and more than 20 cities across the country have passed local measures deprioritizing enforcement. Meanwhile, the FDA has granted Breakthrough Therapy Designation to psilocybin for treatment-resistant depression, and major Phase 3 clinical trials are advancing toward potential federal approval. This page provides the latest statistics on legalization, decriminalization, clinical trial data, and public opinion around psilocybin access in 2026.
U.S. State & City Reform Overview
Oregon's Measure 109, passed alongside Measure 110 in November 2020, created the nation's first state-licensed psilocybin therapy program. After a three-year implementation period, licensed psilocybin service centers began operating in 2023, offering supervised therapeutic sessions administered by trained facilitators. The Oregon Psilocybin Services program is administered by the Oregon Health Authority and represents the most advanced state-level psilocybin regulatory framework in the country.
— Oregon Health Authority, Psilocybin Services Section, 2023Colorado's Proposition 122, the Natural Medicine Health Act, passed in November 2022 with 53% of the vote. The measure decriminalized personal use, possession, and cultivation of psilocybin and three other natural psychedelics (psilocin, ibogaine, and mescaline) for adults 21 and over. It also established a framework for licensed healing centers to provide supervised psilocybin therapy, with the regulatory rollout expected through 2024–2025.
— Colorado Department of Regulatory Agencies, Natural Medicine Division, 2022The city-level reform movement began with Denver, Colorado, which became the first U.S. city to decriminalize psilocybin in May 2019. Other cities quickly followed: Oakland and Santa Cruz (California), Ann Arbor (Michigan), Seattle and Port Townsend (Washington), Detroit (Michigan), and several Massachusetts cities including Cambridge, Somerville, Northampton, and Easthampton. These measures generally direct law enforcement to deprioritize psilocybin-related offenses as the lowest enforcement priority.
— Decriminalize Nature; multiple municipal ordinancesWashington, D.C. passed Initiative 81 in 2020, making psilocybin enforcement the lowest law enforcement priority in the district. While Congress later blocked implementation through a budget rider, the symbolic passage reflects the broad geographic spread of support for reform.
— District of Columbia Board of Elections, 2020California, Washington, and New York have seen state-level legalization bills introduced in recent legislative sessions, though none have passed as of early 2026. Legislative momentum continues to build, with several states expected to introduce or advance reform measures in the 2026–2027 session.
— Psychedelic Science Review, 2025FDA Status & Clinical Trial Data
The U.S. Food and Drug Administration granted Breakthrough Therapy Designation to psilocybin for treatment-resistant depression in 2018 and for major depressive disorder (MDD) in 2019. This designation accelerates the development and review of drugs that show substantial improvement over existing therapies in early clinical trials. It marked a turning point in the federal regulatory approach to psilocybin.
— U.S. Food and Drug Administration, 2018; COMPASS Pathways, 2019Over 10,000 participants are currently enrolled in or have completed active psilocybin clinical trials worldwide, according to ClinicalTrials.gov. The largest Phase 3 programs are being conducted by COMPASS Pathways (COMP360 psilocybin for treatment-resistant depression) and Usona Institute (psilocybin for major depressive disorder). Additional trials are exploring psilocybin for anxiety, PTSD, addiction, eating disorders, and cluster headaches.
— ClinicalTrials.gov (NCT identifiers), 2025The Johns Hopkins Center for Psychedelic & Consciousness Research has reported an 80%+ response rate for treatment-resistant depression in Phase 2 studies, with a significant proportion of participants showing durable improvement lasting at least six months after a single psilocybin session. These results are among the strongest ever recorded for treatment-resistant depression and have formed the basis for Phase 3 trial design.
— Johns Hopkins Center for Psychedelic and Consciousness Research, 2024An NYU Langone Health study involving psilocybin-assisted therapy for patients with cancer-related depression and anxiety found that 83% of participants showed clinically significant reductions in depression and anxiety symptoms at a 6-month follow-up assessment. The study enrolled approximately 80 participants in a double-blind, placebo-controlled design, with results published in leading peer-reviewed journals.
— NYU Langone Health, Department of Psychiatry, 2024Notably, while the FDA rejected MDMA-assisted therapy for PTSD in August 2024 following an advisory committee vote against Lykos Therapeutics' New Drug Application, psilocybin trials have continued without similar setbacks. The FDA's scrutiny appears to have focused on trial design issues specific to the MDMA studies rather than reflecting a broader shift against psychedelic drug development.
— FDA Advisory Committee, August 2024Phase 3 enrollment for COMPASS Pathways' COMP360 program was completed in 2024, with top-line results anticipated in 2025–2026. If results meet efficacy endpoints, a New Drug Application (NDA) submission could follow. Industry analysts project potential FDA approval for psilocybin-assisted therapy as early as 2027–2028.
— COMPASS Pathways Corporate Filings, 2024Public Opinion & Political Support
Public support for therapeutic psilocybin access has risen dramatically over the past decade. A 2023 YouGov poll found that 61% of Americans support legalizing psilocybin for therapeutic or medical use, with support crossing traditional political divides. Support is highest among adults under 45, but majorities or near-majorities across all age groups now favor therapeutic access.
— YouGov America, 2023Support for broader decriminalization (not limited to therapeutic use) is lower but growing. A 2023 Pew Research Center survey found that approximately 40% of Americans support legalizing psilocybin for recreational use, with younger adults significantly more supportive. Support for decriminalization is strongest in Western states, consistent with the geographic pattern of existing reform measures.
— Pew Research Center, 2023Veterans' organizations including Heroic Hearts Project and Veterans Exploring Treatment Solutions (VETS) have been influential advocates for psilocybin access, particularly for treatment-resistant PTSD and traumatic brain injury. The veteran advocacy angle has shifted political discourse, with several Republican state legislators expressing openness to therapeutic psilocybin access specifically.
— Heroic Hearts Project, 2024Global Psilocybin Legal Status
The Netherlands occupies a unique position in global psilocybin policy. While psilocybin-containing mushrooms were banned in 2008, the ban did not extend to truffles (sclerotia), the underground growth form of psilocybin-producing fungi. This legal loophole means psilocybin truffles are openly sold in licensed smart shops across Dutch cities, making the Netherlands one of the most accessible jurisdictions for legal psilocybin access in the world.
— Dutch Opium Act, 2008Jamaica has no specific law criminalizing psilocybin mushrooms, as the Dangerous Drugs Act does not list psilocybin or psilocin as controlled substances. (Psilocybin mushrooms are not explicitly illegal — they simply are not scheduled.) This legal status, combined with Jamaica's existing psychedelic retreat infrastructure (particularly ibogaine), has made it a major destination for psilocybin retreats and therapeutic experiences.
— Jamaican Dangerous Drugs Act, interpretationBrazil has no specific prohibition against psilocybin mushrooms, and the country has a growing psychedelic research community. Several Brazilian universities conduct psilocybin research, and ayahuasca's longstanding legal status in Brazil has created a broader regulatory environment open to psychedelic research. Samoa allows traditional ceremonial use of psychedelic substances, including psilocybin.
— Various national legislationCanada operates under a medical exemption model. Psilocybin remains illegal for recreational use under the Controlled Drugs and Substances Act, but Health Canada has granted special access exemptions for psilocybin-assisted therapy in specific cases, including terminal illness end-of-life distress. Several Canadian companies are conducting clinical trials under these exemption frameworks.
— Health Canada, Controlled Drugs and Substances ActThe 1971 UN Convention on Psychotropic Substances lists psilocybin and psilocin as Schedule I substances, which means signatory nations are obligated to prohibit them. However, several countries (the Netherlands via the truffle loophole, Jamaica through its interpretation, Brazil through lack of specific scheduling) have found pathways around full prohibition. This complex legal landscape means the practical legal status varies dramatically depending on jurisdiction.
— United Nations Convention on Psychotropic Substances, 1971Psychedelic Therapy Market Projections
The global psychedelic therapy market — encompassing psilocybin-assisted therapy, MDMA-assisted therapy, and other psychedelic treatments — is projected to reach approximately $11 billion by 2030. This estimate includes clinic-based therapy, pharmaceutical preparations, training and certification programs, and digital therapeutic tools. Psilocybin is expected to represent the largest share of this market by value, given its broad potential applications and the strong pipeline of clinical evidence.
— Grand View Research, 2025If the FDA approves psilocybin for one or more indications, the U.S. market alone is expected to generate over $7 billion annually by 2030, driven by the large addressable population of patients with treatment-resistant depression, major depressive disorder, and other mental health conditions. The establishment of state-level regulated access frameworks in Oregon and Colorado provides proof-of-concept for the service delivery model.
— Psychedelic Equity Research, 2025Investment in psychedelic drug development has grown significantly, with public and private companies raising over $5 billion cumulatively since 2020. Venture capital investment in psychedelic therapeutics is concentrated in psilocybin, with several companies developing proprietary synthetic psilocybin formulations, delivery methods, and combination protocols.
— Psychedelic Alpha Market Analysis, 2025Beyond therapy, the broader psychedelic ecosystem includes training programs for facilitators, clinic licensing and operation, integration coaching, analytical testing services, and research tools. Oregon's facilitator training programs alone have certified hundreds of practitioners, creating a template that other states are likely to follow.
— Oregon Psilocybin Advisory Board, 2024Key Research Institutions & Findings
The Johns Hopkins Center for Psychedelic & Consciousness Research, founded in 2000 by Dr. Roland Griffiths, is the world's most prolific psilocybin research institution. The center has published over 100 peer-reviewed studies on psilocybin, including landmark papers on psilocybin for anxiety and depression in cancer patients, treatment-resistant depression, smoking cessation, and the neurobiological basis of psychedelic experiences.
— Johns Hopkins Center for Psychedelic and Consciousness ResearchNYU Langone Health's Psychedelic Medicine Research Program has conducted influential studies on psilocybin for cancer-related psychiatric distress. Imperial College London's Centre for Psychedelic Research has produced foundational neuroimaging research showing how psilocybin alters brain network connectivity. The UC Berkeley Center for the Science of Psychedelics (BCSP), established in 2020, focuses on basic neuroscience and public policy research.
— NYU Langone; Imperial College London; UC Berkeley, 2020Multidisciplinary Association for Psychedelic Studies (MAPS) — while primarily focused on MDMA — has been instrumental in the broader psychedelic research renaissance. Their work on clinical trial design, therapist training protocols, and regulatory navigation has created templates that psilocybin researchers have adopted. MAPS-funded research demonstrated that psilocybin could be safely administered in controlled clinical settings, paving the way for the current Phase 3 programs.
— MAPS, 2024Frequently Asked Questions
Which U.S. states have legalized psilocybin in 2026?
Oregon was the first state to legalize psilocybin for therapeutic use (Measure 109, passed 2020), with licensed service centers operational since 2023. Colorado passed Proposition 122 in 2022, decriminalizing personal use and creating a framework for licensed healing centers. Over 20 cities including Denver, Oakland, Santa Cruz, Ann Arbor, Seattle, and Detroit have also passed local decriminalization measures. No state has yet legalized recreational psilocybin as of 2026.
Has the FDA approved psilocybin as a medicine?
The FDA has not yet approved psilocybin as a medicine, but it granted Breakthrough Therapy Designation for psilocybin in 2018 (for treatment-resistant depression) and 2019 (for major depressive disorder). Phase 3 clinical trials are currently underway through COMPASS Pathways and Usona Institute. FDA approval is expected potentially by 2027–2028 if trial results remain positive.
What is the global psychedelic therapy market projected to be worth?
The global psychedelic therapy market is projected to reach approximately $11 billion by 2030. This includes psilocybin-assisted therapy, MDMA-assisted therapy, and other psychedelic treatments for mental health conditions including depression, PTSD, anxiety, and addiction.
Where are magic mushrooms legal outside the United States?
In the Netherlands, psilocybin-containing truffles (sclerotia) are legal and sold in smart shops. Jamaica has no laws against psilocybin mushrooms, making it a destination for psychedelic retreats. Brazil has no specific law against magic mushrooms, and Samoa allows traditional use. Canada currently prohibits psilocybin for recreational use but has granted several special access exemptions for therapeutic use through Health Canada.
Do Americans support psilocybin legalization?
Yes, support has grown significantly. A 2023 YouGov poll found that 61% of Americans support therapeutic psilocybin access. Support for decriminalization is strongest among younger demographics and varies by political affiliation, with majority support now crossing party lines for medical/therapeutic use specifically.
Sources: Oregon Health Authority Psilocybin Services Section; Colorado Department of Regulatory Agencies Natural Medicine Division; YouGov America 2023; Pew Research Center 2023; ClinicalTrials.gov 2025; Johns Hopkins Center for Psychedelic and Consciousness Research; NYU Langone Health Department of Psychiatry; COMPASS Pathways Corporate Filings; Usona Institute; FDA Advisory Committee 2024; Grand View Research 2025; Psychedelic Equity Research 2025; Psychedelic Alpha Market Analysis 2025; MAPS 2024; Decriminalize Nature; various municipal ordinances.